Jo Raskin unpaid staff

Publications Jo Raskin

INSIGHT 2 : a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Source
Future oncology - ISSN 1479-6694- () p.
Author(s)
    Egbert F. Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M. Tho, Xiuning Le, Julien Mazieres, How S. Hin, Masahire Morise, Viola W. Zhu, Daniel Tan, Kristina H. Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M. Schumacher, Niki Karachaliou, Yi-Long Wu

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2) : a multicentre, open-label, phase 2 trial

Source
The lancet oncology - ISSN 1470-2045-25:8 (2024) p. 989-1002
Author(s)
    Yi-Long Wu, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jin-Ji Yang, Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazieres, Lye Mun Tho, Hidetoshi Hayashi, Nguyen Viet Nhung, Puey Ling Chia, Filippo de Marinis, Jo Raskin, Qinghua Zhou, Giovanna Finocchiaro, Anh Tuan Le, Jialei Wang, Christophe Dooms, Terufumi Kato, Ernest Nadal, How Soon Hin, Egbert F. Smit, Martin Wermke, Daniel Tan, Masahiro Morise, Aurora O'Brate, Svenja Adrian, Boris M. Pfeiffer, Christopher Stroh, Dilafruz Juraeva, Rainer Strotmann, Kosalaram Goteti, Karin Berghoff, Barbara Ellers-Lenz, Niki Karachaliou, Xiuning Le, Tae Min Kim

A randomised phase II study of extended pleurectomy/ decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma : EORTC 1205

Source
The European respiratory journal - ISSN 0903-1936-63:6 (2024) p. 1-12
Author(s)
    Jo Raskin, Veerle Surmont, Alexander P.W.M. Maat, Maha Yahia, Sjaak A. Burgers, Yassin Pretzenbacher, Frederic De Ryck, Robin Cornelissen, Houke M. Klomp, Ana Oliveira, Joachim Aerts, Paul Baas, Sandrine Marreaud, Jan van Meerbeeck, Paul van Schil